Want to take quizzes and track your credits?
What are evidence-based approaches to managing preexisting diabetes in pregnancy?
Management considerations vary depending on whether women are in the preconception, pregnancy, or postpartum stage. Optimization of glycemic control prior to pregnancy is a very important step, with a target hemoglobin A1c of less than 6.5% at conception. Insulin is the cornerstone of pharmacotherapy for women with type 1 and type 2 diabetes. Attention to nutrition as well as comorbidities, including obesity, nephropathy, and hypertension, is essential.
Management of diabetes in pregnant women requires careful attention to glycemic control, medication regimens, and comorbidities and planning throughout all stages before, during, and after pregnancy.
The presence of preexisting type 1 or type 2 diabetes in pregnancy increases the risk of adverse maternal and neonatal outcomes, such as preeclampsia, cesarean delivery, preterm delivery, macrosomia, and congenital defects. Approximately 0.9% of the 4 million births in the United States annually are complicated by preexisting diabetes.
Women with diabetes have increased risk for adverse maternal and neonatal outcomes, and similar risks are present with type 1 and type 2 diabetes. Both forms of diabetes require similar intensity of diabetes care. Preconception planning is very important to avoid unintended pregnancies and to minimize risk of congenital defects. Hemoglobin A1c goals are less than 6.5% at conception and less than 6.0% during pregnancy. It is also critical to screen for and manage comorbid illnesses, such as retinopathy and nephropathy. Medications known to be unsafe in pregnancy, such as angiotensin-converting enzyme inhibitors and statins, should be discontinued. Women with obesity should be screened for obstructive sleep apnea, which is often undiagnosed and can result in poor outcomes. Blood pressure goals must be considered carefully because lower treatment thresholds may be required for women with nephropathy. During pregnancy, continuous glucose monitoring can improve glycemic control and neonatal outcomes in women with type 1 diabetes. Insulin is first-line therapy for all women with preexisting diabetes; injections and insulin pump therapy are both effective approaches. Rates of severe hypoglycemia are increased during pregnancy; therefore, glucagon should be available to the patient and close contacts should be trained in its use. Low-dose aspirin is recommended soon after 12 weeks’ gestation to minimize the risk of preeclampsia. The importance of discussing long-acting reversible contraception before and after pregnancy, to allow for appropriate preconception planning, cannot be overstated.
Conclusions and Relevance
Preexisting diabetes in pregnancy is complex and is associated with significant maternal and neonatal risk. Optimization of glycemic control, medication regimens, and careful attention to comorbid conditions can help mitigate these risks and ensure quality diabetes care before, during, and after pregnancy.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Corresponding Author: Anne L. Peters, MD, USC Clinical Diabetes Program, Keck School of Medicine of University of Southern California, 9033 Wilshire Blvd, Ste 406, Los Angeles, CA 90211 (firstname.lastname@example.org).
Accepted for Publication: April 3, 2019.
Author Contributions: Dr Peters had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Alexopoulos, Peters.
Acquisition, analysis, or interpretation of data: Alexopoulos, Blair.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: All authors.
Administrative, technical, or material support: Alexopoulos, Blair.
Conflict of Interest Disclosures: Dr Peters reported grants from AstraZeneca, Dexcom, and MannKind and consulting for Abbott Diabetes Care, Eli Lilly, Livongo, MannKind, Medscape, Novo Nordisk, Omada Health, Sanofi and Zafgen. No other disclosures were reported.
Funding/Support: This work was supported by the National Institutes of Health awards T32DK007012 (Dr Alexopoulos) and T32HL007609 (Dr Blair).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The contents of this article are solely the responsibility of the authors and do not necessarily represent the official view of the National Institutes of Health.
You currently have no searches saved.